Synapse - Chau Dang

Results (272)

Epirubicin: Is it like doxorubicin in breast cancer? A clinical review

Journal Article

Khasraw, M.; Bell, R.; Dang, C.
Breast (2012)

Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103

Meeting Abstract

Schneider, B. P.; Li, L.; Miller, K.; Flockhart, D.; Radovich, M.; Hancock, B. A.; Kassem, N.; Foroud, T.; Koller, D. L.; Badve, S. S.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)

Meeting Abstract

Dang, C. T.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Cardiac outcomes of patients on adjuvant weekly paclitaxel (T) and trastuzumab (H) for node negative, HER2 positive breast cancer (BCA)

Meeting Abstract

Dang, C.; Tolaney, S.; Najita, J.; Gelman, R.; Yardley, D.; Marcom, K.; Albain, K.; Rugo, H.; Miller, K.; Ellis, M.; more...
Cancer Research (2011)

Fulltext@MSK | Save

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

Journal Article

Gucalp, A.; Sparano, J. A.; Caravelli, J.; Santamauro, J.; Patil, S.; Abbruzzi, A.; Pellegrino, C.; Bromberg, J.; Dang, C.; Theodoulou, M.; more...
Clinical Breast Cancer (2011)

Fulltext@MSK | Save

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

Journal Article

Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
Annals of Oncology (2011)

Fulltext@MSK | Save

The end of an era: Shall we move forward?

Journal Article

Dang, C.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer - The Henderson article reviewed [Can we abandon anthracyclines for early breast cancer patients?]

Journal Article

Morris, P. G.; Hudis, C. A.; Dang, C. T.
Oncology (Norwalk) (2011)

Fulltext@MSK | Save

Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib

Journal Article

Morris, P. G.; Chen, C.; Steingart, R.; Fleisher, M.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Abbruzzi, A.; Lehman, R.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

Journal Article

Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save